Endocrinology Search
Endocrinology Endocrinology
osteoporosis
OSTEOPOROSIS
Osteoporosis is a progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.

Osteoporosis References

  1. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001 Jul;44(7):1496-1503. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11465699
  2. Bonura F. Prevention, screening and management of osteoporosis: an overview of the current strategies. Postgrad Med. 2009 Jul;121(4):005-17. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19641263
  3. Brown JP, Fortier M, et al; Osteoporosis Guidelines Committee. Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can. 2006 Feb;28(2)(Suppl 1):S95-S112. http://www.ncbi.nlm.nih.gov/pubmed/?term=16626523. PMID: 16626523
  4. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003 Apr;67(7):1521-1526. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 12722852
  5. CJ Haines, S Fan, GWK Tang, et al. Guidelines for the administration of hormone replacement therapy. The Hong Kong College of Obstetricians and Gynaecologists. Hong Kong Med J. 1999 Jun;5(2):195-199. http://www.hkmj.org/article_pdfs/hkm9906p195.pdf. PMID: 11821592
  6. Compston J. Clinical and therapeutic aspects of osteoporosis. Aug 05, 2009. Eur J Radiol. 2009 Sep;71(3):388-391. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19660883
  7. Compston J, Cooper A, Cooper C, et al; National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009 Feb;62(2):105-108. doi: 10.1016/j.maturitas.2008.11.022. PMID: 19135323
  8. Dell RM, Greene D, Anderson D, et al. Osteoporosis disease management: what every orthopaedic surgeon should know. J Bone Joint Surg Am. 2009 Nov;91(Suppl 6):79-86. doi: 10.2106/JBJS.I.00521. PMID: 19884415
  9. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002 Jun;359(9322):2018-2026. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 12076571
  10. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Jul 26, 2010. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515-1526. http://www.rheumatology.org/practice/clinical/guidelines/GIOP_Guidelines_Nov_2010.pdf. Accessed 13 Sep 2013. PMID: 20662044
  11. Delmas PD, Eastell R, Garnero P, et al; Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11(Suppl 6):S2-S17. PMID: 11193237
  12. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003 Nov;9(6):544-564. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 14715483
  13. Kanis JA, Burlet N, Cooper C, et al; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008 Apr;19(4):399-428. http://www.ncbi.nlm.nih.gov/pubmed/?term=18266020. PMID: 18266020
  14. Kanis JA, McCloskey EV, Johansson H, et al. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009 Aug;5(8):425-431. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19648943
  15. Lau EM, Sambrook P, Seeman E, et al. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR J Rheumatol. 2006 Apr;9(1):24-36
  16. Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone. 2006;8(1):40-53. PMID: 17591575
  17. Leweicki EM. Managing osteoporosis: challenges and strategies. Cleve Clin J Med. 2009 Aug;76(8):457-466. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19652039
  18. Leweicki EM. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am. 2008 Jun;35(2):301-315. doi: 10.1016/j.ogc.2008.03.007. PMID: 18486843
  19. Leweicki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 2009 Oct;18(10):1615-1626. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 19857095
  20. Mayes SL. Review of postmenopausal osteoporosis pharmacotherapy. Nutr Clin Pract. 2007 Jun;22(3):276-285. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17507728
  21. Mazziotti G, Giustina A, Canalis E, et al. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1404-1412. doi: 10.1590/S0004-27302007000800028. PMID: 18209880
  22. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008 Mar;6(1):012-16. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 18430395
  23. Muenier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004 Jan;350(5):459-468. http://www.nejm.org. PMID: 14749454
  24. National Institute of Health. Osteoporosis prevention, diagnosis and therapy. NIH Consens Statement. 2000 Mar;17(1):001-36. http://consensus.nih.gov/2000/2000osteoporosis111html.htm.
  25. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May;344(19):1434-1441. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11346808
  26. North American Menopause Society (NAMS). Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Mar;17(2):242-255. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20154637
  27. Poole KES, Compston JE. Osteoporosis and its management. BMJ. 2006 Dec;333(7581):1251-1256. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 17170416
  28. Reginster J, Lecart M, Deroisy R, et al. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert Opin Investig Drugs. 2004 Jul;13(7):857-864. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 15212623
  29. Rahmani P, Morin S. Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ. 2009 Nov;181(11):815-820. doi: 10.1503/cmaj.080709. PMID: 19841053
  30. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov;357(20):2028-2039. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 18003959
  31. Sambrook PN, Seeman E, Phillips SR, et al; Osteoporosis Australia; National Prescribing Service. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust. 2002 Apr;176(Suppl):S1-S16. PMID: 12049064
  32. Seeman E, Eisman J. Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust. 2004 Mar;180(6):298-303. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 15012571
  33. South-Paul JE. Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Physician. 2001 Mar;63(6):1121-1128. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11277549
  34. South-Paul JE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician. 2001 Mar;63(5):897-904, 908. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 11261866
  35. Stránský M, Rysavá L. Nutrition as prevention and treatment of osteoporosis. Physiol Res. 2009;58(Suppl 1):S7-S11. http://www.ncbi.nlm.nih.gov/pubmed/?term=19857038. PMID: 19857038
  36. The Hong Kong College of Obstetricians and Gynaecologists. Guidelines for the administration of hormone replacement therapy. Number 2. 2003 Jan. http://hkcog.obg.cuhk.edu.hk.
  37. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2007 Jul;19(4):370-375. PMID: 17551369
  38. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. 2010. Endocr Pract. 2010 Dec;16(Suppl Suppl 3):1-37. http://www.ncbi.nlm.nih.gov/pubmed/21224201. PMID: 21224201
  39. North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010 Jan;17(1):25-54. http://www.ncbi.nlm.nih.gov/pubmed. PMID: 20061894
  40. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  41. MedWormhttp://www.medworm.com/rss/index.php/OBGYN/29/http://www.medworm.com/rss/medicalfeeds/specialities/OBGYN.xml
  42. Ministry of Health Malaysia, Academy of Medicine Malaysia, Malaysian Osteoporosis Society. Clinical guidelines on management of osteoporosis 2012. http://www.osteoporosis.my. 2012. Accessed 18 Jun 2013.
  43. Finkelstein JS. Clinical manifestations, diagnosis, and evaluation of osteoporosis in men. UpToDate. http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-osteoporosis-in-men. 2010. Accessed 11 Jan 2011.
  44. Malaysian Osteoporosis Society, Academy of Medicine Malaysia. Clinical practice guidelines of management of osteoporosis. http://www.osteoporosis.my/GUI/pdf/CG_Mgmt_Osteoporosis_2012-0912.pdf. 2012. Accessed 11 Jun 2013.
  45. Malaysian Osteoporosis Society, Academy of Medicine Malaysia. Clinical practice guidelines of management of osteoporosis. http://www.msr.org.my/html/CPG_on_Osteoporosis-2006.pdf. 2006. Accessed 18 May 2010.
  46. Academy of Medicine Malaysia, Malaysian Osteoporosis Society. Clinical practice guidelines on the management of osteoporosis. http://www.acadmed.org.my. 2000.
  47. Ministry of Health Singapore. Clinical practice guidelines: osteoporosis. MOH (Singapore). http://www.moh.gov.sg. 2008. Accessed 26 May 2010.
  48. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org. 2008.
  49. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://nof.org/files/nof/public/content/resource/913/files/580.pdf. 2013
  50. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://nof.org/files/nof/public/content/file/344/upload/159.pdf. 2010
  51. Schnitzer TJ. Diagnosis and treatment for osteoporosis: current status and expectations for the new millennium. http://www.medscape.com/view program/605_pnt. Dec 2001
  52. Finkelstein JS. Diagnosis and evaluation of osteoporosis in men. UpToDate. http://www.uptodate.com/online/content/topic.do?topicKey=bone_dis/2229&selectedTitle=1~150&. 2010. Accessed 11 Jan 2011.
  53. National Osteoporosis Foundation. Foundation for Osteoporosis Research and Education: osteoporosis guidelines for the physician. 4th ed. http://www.nof.org. 2002
  54. Compston J, Barlow D, et al for the Guidelines Working Group the Royal College of Physicians, The Bone Tooth Society of Great Britain and The National Osteoporosis Society. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. http://www.rcplondon.ac.uk. Dec 2002.
  55. National Osteoporosis guideline Group and the International Osteoporosis Foundation. Guidelines in practice. http://shef.ac.uk/NOGG/2009_IOF-NOGG_workshops_Report.pdf. 2009. Accessed 28 Sep 2011.
  56. Reginster JY. New agents for the treatment of osteoporosis. http://www.medscape.com. Jan 2003.
  57. Osteoporosis prevention, diagnosis and therapy. National Institute of Health (NIH) consensus statement. Mar 27-29, 2000:1-36. http://www.opd.od.nih.gov.
  58. Finkelstein JS. Overview of osteoporosis in men. UpToDate. http://www.uptodate.com. 2003.
  59. National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE. http://publications.nice.org.uk. Aug 2012. Accessed 11 Jun 2013.
  60. Rosen HN. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. http://www.uptodate.com. 2002.
  61. Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. http://www.uptodate.com. May 2011. Accessed 22 Sep 2011.
  62. Lie D. Prevention and treatment of osteoporosis in long-term glucocorticoid users. http://www.medscape.com. Aug 2002.
  63. Finkelstein JS. Treatment of osteoporosis in men. UpToDate. http://www.uptodate.com/contents/treatment-of-osteoporosis-in-men. 2010. Accessed 11 Jan 2011.
  64. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jun;97(6):1802-1822. doi: 10.1210/jc.2011-3045. PMID: 22675062
  65. Compston J, Bowring C, Cooper A, et al; National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013 Aug;75(4):392-396. doi: 10.1016/j.maturitas.2013.05.013. Accessed 24 Apr 2014. PMID: 23810490
  66. OSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip I, Cheung SK, Cheung TC, et al; Osteoporosis Society of Hong Kong. The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J. 2013 Apr;19(Suppl 2):1-40. http://www.hkmj.org. Accessed 22 May 2014. PMID: 23535738
  67. Malaysian Osteoporosis Society, Academy of Medicine Malaysia, and Ministry of Health Malaysia. Clinical guidance on management of osteoporosis 2012. Revised 2015. Malaysian Society of Rheumatology (MSR). http://www.msr.my. 2015. Accessed 04 Sep 2015.
  68. Kanis JA, McCloskey EV, Johansson H, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. http://www.ncbi.nlm.nih.gov. Accessed 02 Oct 2014. PMID: 23079689
  69. Li-Yu J, Perez EC, Canete A, et al; Osteoporosis Society of the Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis. Summary of the consensus statements on osteoporosis prevention, diagnosis, and treatment in the Philippines. Journal of ASEAN Federation of Endocrine Societies. http://www.asean-endocrinejournal.org/. 2012.
  70. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42. doi: 10.4158/EP161435.GL. Accessed 27 Mar 2017. PMID: 27662240
  71. Qaseem A, Forciea MA, McLean RM, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women; a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017 Jun 6;166(11):818-839. doi: 10.7326/M15-1361. PMID: 28492856
  72. Hauk L. Treatment of low BMD and osteoporosis to prevent fractures: updated guideline from the ACP. Am Fam Physician. 2018 Mar 1;97(5):352-353. https://www.aafp.org. PMID: 29671503
  73. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. PMID: 26350171
  74. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. Am Fam Physician. 2015 Aug;92(4):261-268. http://www.aafp.org. PMID: 26280231
  75. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2. Accessed 2 Oct 2014. PMID: 25182228
  76. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. P T. 2018 Feb;43(2):92-104. Accessed 07 Jan 2019. PMID: 29386866
  77. Finkelstein JS, Yu EW. Treatment of osteoporosis in men. UpToDate. http://www.uptodate.com/. Dec 2018.
  78. Rosen HN. Selective estrogen receptor modulators for prevention and treatment of osteoporosis. UptoDate. http://www.uptodate.com/. Dec 2018.
  79. Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. UptoDate. http://www.uptodate.com/. Dec 2018. Accessed 07 Jan 2019.
  80. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010 Nov;182(17):1864-1873. doi: 10.1503/cmaj.100771. PMID: 20940232
  81. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 May;104(5):1595-1622. doi: 10.1210/jc.2019-00221. Accessed 23 May 2019. PMID: 30907953
  82. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020 Mar 1;105(3):pii: dgaa048. doi: 10.1210/clinem/dgaa048. Accessed 17 Mar 2020. PMID: 32068863
  83. Bethel M. Osteoporosis. Medscape. https://emedicine.medscape.com. 26 Sep 2019. Accessed 07 Jul 2020.
  84. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Accessed 07 Jul 2020. PMID: 28585373
  85. Diez-Perez A, Adachi JD, Agnusdei D, et al; IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int. 2012 Dec;23(12):2769-2774. doi: 10.1007/s00198-012-2093-8. Accessed 07 Jul 2020. PMID: 22836278
  86. Straseski JA. Osteoporosis. ARUP Consult. https://arupconsult.com/content/osteoporosis. Jan 2020. Accessed 07 Jul 2020.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Cancer patients in dire straits amid COVID-19 pandemic
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
Probiotic supplements beneficial for T2DM patients
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
SGLT-2 inhibitors may induce diabetic ketoacidosis
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Cabotegravir superior to TDF/FTC for HIV prevention
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.